Skip to content

Sympathetic Neural Outflow During Xenon Anesthesia in Humans

Sympathetic Neural Outflow During Xenon Anesthesia in Humans

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01043419
Enrollment
8
Registered
2010-01-06
Start date
2010-01-31
Completion date
2010-03-31
Last updated
2025-09-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sympathetic Nervous System

Keywords

Xenon Anesthesia, LENOXe™ (xénon 100 % v/v) anesthesia, Muscle Sympathetic Activity, Baroreflex reagibility

Brief summary

The purpose of this study is to test the hypothesis that sympathetic neural outflow to muscles as well as a sympathetic baroreflexes are not altered during xenon anesthesia in Healthy Volunteers.

Detailed description

Objectives for this study : * Main Objective : Influence of Xenon anesthesia on Sympathetic Nervous Activity * Secondary Objectives : Security under LENOXe™ (xénon 100 % v/v) anesthesia

Interventions

DRUGxenon

Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes

Sponsors

Air Liquide Santé International
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No

Inclusion criteria

* Healthy volunteers \> 18 years and \< 65 years of age * ASA physical status I * Legal competence * for whom the consent form has been signed

Exclusion criteria

* Healthy volunteers \< 18 years and \> 65 years of age * Pregnancy, lactation period or missing secure anticonvulsive therapy * Missing legal competence * Participation in other clinical trials * Contraindications as mentioned on §4.3 of the SPCs of LENOXe™ (xénon 100 % v/v) * Any medication especially of Sildenafil (Viagra®) or other potency remedy * Existing relationship of dependency to the sponsor or the investigator

Design outcomes

Primary

MeasureTime frame
Muscle Sympathetic Activity (MSA)and Baroreflex reagibility under Xenon Anesthesia in comparison to awake30 minutes

Secondary

MeasureTime frame
Arterial blood pressure, Heart frequency, Arterial O2 and CO2 Saturation,Skin conductance,Concentration of plasma catecholamines, Angiotensin & Renin under Xenon Anesthesia in comparison to awakeIn continuous during 30 minutes

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026